Literature DB >> 14758504

Irradiated homologous costal cartilage: versatile grafting material for rhinoplasty.

Ferit Demirkan1, Emrah Arslan, Sakir Unal, Alper Aksoy.   

Abstract

For most surgeons, nasal septal cartilage is the first choice in septoplasty. However, when this source is depleted, an alloplastic implant material might be preferable over other autogenous donor sites in order to avoid additional scars, morbidity, and lengthened operating time. In the alloplastic spectrum, irradiated costal cartilage (ICC) has certain advantages. Herein, we present our results with ICC in a wide range of septorhinoplasties to show its versatility and reliability. Sixty-five patients were included in the study. There were 42 male and 23 female patients. According to the indications, there were four groups of patients: (I) secondary septorhinoplasty (n = 24), (II) traumatic deformity (n = 21), (III) primary septorhinoplasty (n = 13), (IV) deformity due to previous septal surgery (n = 7). The mean follow-up period was 33 months. No significant resorption was detected in any of the patients. Minor complications developed in four cases (6%), including deformity in the dorsal graft, excessive graft length, and erythematous nasal tips. Aesthetic and functional results were satisfactory in the remaining cases. The low incidence of major complications and the versatility of ICC make it a safe and reliable source of cartilage graft for both primary and secondary septorhinoplasties when autogenous septal cartilage is either insufficient or unsuitable.

Entities:  

Mesh:

Year:  2003        PMID: 14758504     DOI: 10.1007/s00266-003-0118-6

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  1 in total

1.  Comparison of Autologous vs Homologous Costal Cartilage Grafts in Dorsal Augmentation Rhinoplasty: A Systematic Review and Meta-analysis.

Authors:  Peter M Vila; Latoya M Jeanpierre; Christopher J Rizzi; Lauren H Yaeger; John J Chi
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-04-01       Impact factor: 6.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.